Skip to Main Content

Paper Details

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Gynecol Oncol
194
2017
Author NameAffiliation
Iain A McNeishInstitute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre
Isabelle Ray-CoquardCentre Leon Berard and University Claude Bernard
James D BrentonCancer Research UK Cambridge Institute, University of Cambridge
Gottfried E KonecnyDavid Geffen School of Medicine, University of California Los Angeles
  • 1 - 4

Datasets

Release 1.2